Z$$Z,X Qx x @BT|[B? g_:B1$&eqBi wxDgK d 4?~Xp r\4dQx|WV {1VKl&Kq:V:l @r&a ~hg*I~%~h 4` ~6+n2D+5 ]gh^ IIaI8SIUbII=IIwOpI/ SjPjz Tkf&eDT mv`j%n!vc-! {pV2pT23V5T3{{ @b@*\\Kb,MK /9ob97y+ jF~~d!~~k. _Qn Gge=RNe t, %:6 89, 4sx8_ %p%FIczc WU HR,Z V-kIT _dy #NrSrlrrS zH (5ot ,F}5b j]U.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/6%`omut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.